Study confirms long-lasting anticancer benefit of zoledronic acid for women with early-stage breast cancer

Women with early-stage hormone receptor-sensitive breast cancer* given zoledronic acid, a bone strengthening drug, in addition to standard hormone therapy for 3 years following surgery are at significantly (32%) less risk of their cancer returning, and the effect is long lasting, according to the long-term results of the landmark Austrian Breast and Colorectal Cancer Study Group trial-12 (ABCSG-12) published Online First in The Lancet Oncology.

Read the whole article on Physorg

More from Physorg